Guidelines for supportive care in multiple myeloma 2011

Snowden, John A.; Ahmedzai, Sam H; Ashcroft, John; D’Sa, Shirley; Littlewood, Timothy; Low, Eric; Lucraft, H. H.; Maclean, Rhona; Feyler, Sylvia; Pratt, Guy; Bird, Jennifer M.; Forum, UK Myeloma

doi:10.1111/j.1365-2141.2011.08574.x

Cited by 182 publications

(223 citation statements)

References 165 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Guidelines are available addressing the management of pain in patients with MM including detailed recommendations for the use of analgesics [98]. Key points in the pharmacologic management of pain in MM patients are the need for frequent reassessment of pain intensity and appropriateness of treatment employed, avoidance of nonsteroidal antiinflammatory drugs due to risk of renal impairment, and anticipation of side effects from narcotics (particularly constipation, emesis and sedation) in this mostly elderly population.…”

Section: Do Manage Painmentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population‐level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide “do's and don'ts” management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM‐related complications. Am. J. Hematol. 91:101–108, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Do Manage Painmentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…1 Recently, much attention has been drawn to the changing spectrum of infections in MM, possibly related to the more intensive treatment and new classes of therapeutic agents of recent years. [2][3][4] According to recent studies, MM is always preceded by monoclonal gammopathy of undetermined significance (MGUS). 5 While patients with MGUS are asymptomatic, they have increased morbidity and mortality compared to the general population.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Kristinsson¹,

Tang²,

Pfeiffer³

et al. 2011

Haematologica

122

View full text Add to dashboard Cite

“…Furthermore, associated enhanced supportive care measures have also been developed to improve MM management [7,8]. BOR is approved for the treatment of previously untreated and relapsed MM, THAL in combination with dexamethasone for the treatment of previously untreated MM, and LEN in combination with dexamethasone for the treatment of MM following at least one prior therapy.…”

Section: Introductionmentioning

confidence: 99%

Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

et al. 2013

View full text Add to dashboard Cite

Background. Treatment of multiple myeloma has dramatically improved with the introduction of bortezomib (BOR), thalidomide (THAL), and lenalidomide (LEN). Studies assessing health care costs, particularly economic burden on patients, are limited. We conducted a claims-based, retrospective analysis of total health care costs as well as patient burden (patient out-of-pocket costs and number of ambulatory/hospital visits) associated with BOR/THAL/LEN treatment versus other therapies (OTHER). Conclusions. Adjusted analyses of real-world claims data show that total health care costs, as well as patient out-of-pocket costs, are higher with THAL/LEN treatment episodes than with BOR/OTHER therapies. Additionally, similar rates of ambulatory visits suggest that any perceived advantage in patient convenience of the orally administered drugs THAL/LEN is not supported by these data. The Oncologist 2013;18:37-45 Implications for Practice: In addition to efficacy and safety considerations, economic factors associated with novel treatments are important issues for payers and patients. Claims data provide real-world insight into health care costs associated with treatment for multiple myeloma. In this study, total health care costs and patient out-of-pocket costs were measured during one year post-initiation and analyzed per treatment episode. Adjusted for patient characteristics, comorbidities, and line of treatment, the costs of "other" therapies (i.e., other chemotherapy or radiotherapy) and bortezomib were similar, but the costs of thalidomide or lenalidomide treatment were significantly higher. Despite different routes of administration for bortezomib (intravenous), and thalidomide and lenalidomide (oral), the number of ambulatory visits (i.e., clinic/physician office and hospital outpatient visits) appeared similar across therapies with the only significant difference being between the rates for lenalidomide and "other" treatment. These data show differential real-world costs and patient burden associated with these treatments and may support decision-making with regard to multiple myeloma treatment.

show abstract

Guidelines for supportive care in multiple myeloma 2011

Cited by 182 publications

References 165 publications

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

Contact Info

Product

Resources

About